Levels of evidence: a comparison between top medical journals and general pediatric journals

Dustin A Jacobson1, Kunal Bhanot2, Blake Yarascavitch3

  • 1Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada. jacobson.dustin@gmail.com.

BMC Pediatrics
|April 17, 2015
PubMed

Insights

Pediatric clinical literature in high-impact journals offers higher levels of evidence (LOE) and better-quality randomized control trials. Focusing on these resources can improve clinical decision-making.

Area of Science:

  • Medical Research
  • Clinical Evidence
  • Pediatric Literature

Background:

  • Clinicians require high levels of evidence (LOE) due to the vast amount of published research.
  • Assessing LOE in pediatric literature is crucial for effective clinical practice.

Purpose of the Study:

  • To determine the level of evidence (LOE) in pediatric literature.
  • To compare LOE between general pediatric journals and high-impact clinical journals.

Main Methods:

  • Reviewed pediatric articles from April 2011 to March 2012 in high-impact clinical journals (HICJ) and general pediatric journals (GPJ).
  • Evaluated articles for LOE, subspecialty, author count, and study centers.
  • Assessed eligible Level I randomized control trials using Consolidated Standards of Reporting Trials (CONSORT) guidelines.

Main Results:

  • 804 of 6511 articles met inclusion criteria (68 in HICJ, 736 in GPJ).
  • Pediatric articles in The Lancet showed significantly higher LOE than GPJ (p < 0.05).
  • HICJ demonstrated significantly higher average CONSORT scores than GPJ (15.2 vs. 13.6, p < 0.001).

Conclusions:

  • High-impact clinical journals (HICJ) provide the highest LOE and quality for pediatric randomized control trials.
  • Pediatric studies in HICJ represent a small fraction of published data.
  • Adhering to CONSORT criteria and promoting high LOE studies can enhance clinical impact.
Abstract

Related Concept Videos

Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
737
The Evidence for Evolution02:55

The Evidence for Evolution

Genetic variations accumulating within populations over generations give rise to biological evolution. Evolutionary changes can result in the formation of novel varieties and entire new species. These changes are responsible for the diverse forms of life inhabiting the planet. The evidence for evolution suggests that all living organisms descended from common ancestors.
50.7K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
360
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
391
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
838
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
720